10 studies found for:    hu14.18
Show Display Options
Rank Status Study
1 Completed Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Condition: Melanoma
Intervention: Drug: hu14.18-IL2
2 Completed
Has Results
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: hu14.18-Interleukin-2 fusion protein
3 Active, not recruiting Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Condition: Recurrent Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein;   Drug: isotretinoin;   Biological: sargramostim;   Other: laboratory biomarker analysis
4 Unknown  Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
Condition: Melanoma (Skin)
Intervention: Biological: hu14.18-IL2 fusion protein
5 Completed Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
Conditions: Melanoma (Skin);   Neuroblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Biological: hu14.18-IL2 fusion protein
6 Recruiting A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: Humanized anti-GD2 antibody;   Drug: Chemotherapy;   Other: Cytokines;   Biological: Natural killer cells
7 Recruiting Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody
Conditions: Ewings Family of Tumors;   Melanoma;   Neuroblastoma;   Osteosarcoma
Intervention:
8 Recruiting Therapy for Children With Advanced Stage Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
9 Not yet recruiting A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
Conditions: Neuroblastoma;   Lymphoma;   High-risk Tumor
Interventions: Device: CD133+ selected autologous stem cell infusion;   Biological: IL-2;   Biological: hu14.18K322A;   Drug: Busulfan;   Drug: Melphalan;   Biological: GM-CSF;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Carboplatin;   Device: Haploidentical natural killer cell infusion;   Biological: G-CSF;   Drug: Etoposide phosphate
10 Recruiting A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
Conditions: Neuroblastoma;   Melanoma;   Osteosarcoma;   Ewing Sarcoma
Intervention: Biological: Anti-G2 antibody

Indicates status has not been verified in more than two years